Kairos Pharma, Ltd. (KAPA)

Market Cap	9.64M +1.9%
Revenue (ttm)	n/a
Net Income	-5.84M
EPS	-0.30
Shares Out	21.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,161
Open	0.4410
Previous Close	0.4400
Day's Range	0.4371 - 0.4589
52-Week Range	0.4300 - 2.1100
Beta	n/a
Analysts	Buy
Price Target	8.00 (+1,677.78%)
Earnings Date	May 13, 2026

About KAPA

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company’s pro...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 16, 2024
• Employees: 4
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: KAPA
• Website: https://kairospharma.com

Analyst Summary

According to 2 analysts, the average rating for KAPA stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 1,677.78% from the latest price.

Price Target

$8.0

(1,677.78% upside)

Analyst Consensus: Buy